1. Question: Please explain what you mean when you say that an entrant be registered to do business and be in good standing in the State of Ohio.

Answer: Regarding registration to do business in Ohio, please see https://www.sos.state.oh.us/businesses/filing-forms--fee-schedule/. A non-Ohio entity would choose Form 530A (for profit) and Form 530B (for non-profit). Registration fee is US\$99 for regular service (3-7 business days); there additional fees to expedite processing.

2. Question: When do I need to register to do business in Ohio, before submitting a response or before accepting an award (if I am chosen to receive an award)?

Answer: You do not need to register to do business in Ohio in order to submit a challenge response. If your submission is selected as a winner, you would need to register to do business in Ohio before accepting the award. Your registration with Ohio will require a Certificate of Good Standing, from the state in which your organization is incorporated, which must not be older than 90 days prior to the date in which you submit your registration to Ohio.

3. Question: Who is eligible to compete for the Product Phase?

Answer: Only winners of the Challenge Phase are eligible to compete in the Product Phase.

4. Question: Do I have to fill in each section of the online response form or can I prepare my submission as an attached document?

Answer: You can do either. Please pay attention to the list of Elements required (table below). For an attached proposal, please adhere to the page limits using a legible font not smaller than 10-point. Remember that you are also allowed to upload up to three supporting documents and provide a video link.

Element	Page Limit
Non-confidential abstract (for public disclosure) summarizing your approach and how it addresses overdose prevention, treatment, overdose avoidance, and/or overdose response	1
More detailed (preferably non-confidential) description of your approach and its underlying technology. For Trade Secrets, see Official Rules, section 12.	3
Explain how your approach meets Key Attributes for Topic to which you are responding	1
Estimate the impact on the opioid crisis—how many people your approach could help	1
Explain why your approach may be better or more advanced than similar or competing strategies	1
Summarize your efforts to date and current state of readiness with evidence to demonstrate effectiveness (results of clinical trials, animal studies, product beta testing, peer reviewed results)	5
Summary of steps, resources, and time required to advance your solution for deployment, including efforts in next phases (if you win Challenge Phase; if you win Product Phase)	4
Team description	2
Linked video and uploaded supporting documents	

5. Question: What will be required of Challenge Phase winners to be able to compete for Product Phase awards?

Answer: Challenge Phase winners will be required to execute an NDA with NineSigma and submit a more detailed plan that explains tasks and timeline you plan to follow to continue development of your technology to enable deployment or commercialization. You should explain what you plan to do, deadlines, and deliverables. Then, during the period from approximately October 2018 to July 2019, you work against your plan. You also need to explain how you are going to involve an Ohio in-state entity in your effort.

By July 31, 2019, you will submit another response (report) in which you discuss progress made against your plan. You should provide evidence that supports a path toward deployment.

You should also be prepared to present a 30-minute progress report by web conference to the judges who will be selecting who receives the Product Phase award (4 1-million \$ prizes).

Further details will be available before the Challenge Phase deadline

Winners of Product Phase Award will be obligate to deliver periodic reports to NineSigma from Q4 2019 through Q4 2021. NineSigma will ask you to provide some data that will be disclosed to the State of Ohio. Further details will be available before Product Phase starts.